EU team launches PhI trial of Parkinson's vaccine; GAVI commits up to $300M for Ebola vaccines;

> EU consortium SYMPATH has begun recruiting for a Phase I study of AFFiRiS' Parkinson's vaccine candidate AFFITOPE PD03A. More

> GAVI says it is committing up to $300 million to buy Ebola vaccines and is ready to begin procurement as soon as the World Health Organization (WHO) recommends one for use. Report

> The FDA has awarded Immunovaccine's ovarian cancer vaccine, DPX-Survivac, its fast-track designation. Release

> VaxInnate has kicked off a Phase Ib/II clinical trial of its quadrivalent seasonal influenza vaccine candidate, VAX2012Q, in the elderly. Release

> Vical ($VICL) has completed enrollment in a Phase I/II clinical trial of its therapeutic HSV-2 vaccine. Release

> The National Cancer Institute has awarded MRIGlobal a $3 million contract to produce an HPV vaccine. Report

> The Indonesian Ministry of Health has rolled out Bio Farma's pentavalent vaccine, added to the country's immunization program last year, across all 33 provinces. More

And Finally... The latest entrant into Islamic finance is leading the industry in the new direction of socially responsible investment. More

Suggested Articles

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.

Participation in clinical trials among Black people is low, FDA statistics show, even as drugmakers prioritize including them in COVID-19 shot trials.